Home / Market News / $THC
benzinga Corporate Catalyst Impact 55/100 ● positive

Guggenheim Maintains Buy on Tenet Healthcare, Raises Price Target to $307

Oct 16, 2026, 12:31 PM UTC · Primary ticker $THC

Guggenheim analyst Jason Cassorla reiterated a 'Buy' rating on Tenet Healthcare (THC) and increased the price target from $283 to $307. This indicates continued analyst confidence in the company's performance and future prospects, which could provide a modest positive sentiment boost for the stock.

Guggenheim analyst Jason Cassorla maintained a 'Buy' rating on Tenet Healthcare (THC) and raised the price target from $283 to $307. This action signals a continued positive outlook from a prominent financial institution regarding THC's valuation and operational performance. For traders, this could lead to a short-term positive bump in stock price due to increased investor confidence, and potentially a longer-term positive trend if other analysts follow suit or the company meets/exceeds expectations implied by the new target. The primary impact is on THC shareholders and potential investors, as it suggests an upward revision in the perceived intrinsic value of the company.

$THC positive Analyst price target increase and 'Buy' rating maintenance
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.